Key result
This is an editorial message summarizing the journal's progress and goals for 2023, with no clinical data reported.
Key points are not available for this paper at this time.
Design
Editorial
Highlights evolving thrombosis journal landscape; leaves open impact on future research directions.
A happy new year to everyone from everyone at Thrombosis & Haemostasis , and with the new year, we see new challenges and some changes in the journal. As with our traditional new year's message, we aim to summarize our journey in the last year and look forward to 2023.[ 1 ] [ 2 ] [ 3 ] [ 4 ] Another year has quickly passed, and as we emerge into more (three-dimensional) in-person meetings rather than the two-dimensional virtual meetings of various platforms, the journal also continues to grow. Again, our editorial priorities are to ensure better manuscripts are published and faster turnaround of papers with more emphasis on priority ranking, leading to a higher rejection rate. We have also grown our open access journal, TH Open , which has had a steady growth of submissions and good quality publications that have been transferred from the main Thrombosis & Haemostasis journal. Our acceptance rate is <25%, and our mean time to first editorial decision is 24 days. As editors and authors ourselves, we appreciate the need for speedy decision making, and our goal remains to get the time to first decision <21 days. Our submissions remain fairly steady (notwithstanding a COVID-related peak in 2020) keeping the editorial team busy. Publication History Article published online: 10 January 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
No takes yet. Share an insight, caveat, or question.
Lip et al. (2023) reported an editorial. This is an editorial message summarizing the journal's progress and goals for 2023, with no clinical data reported.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: